MoonLake Immunotherapeutics business relationships
Companies named in MoonLake Immunotherapeutics’s 10-K filed 2026-02-25, and public companies whose annual reports name MoonLake Immunotherapeutics. Each link shows the sentence it came from. Scores are Engagemii’s AI visibility scores.
- AEO visibility
- 4.9 / 10
- AI naming
- 23 / 100 Top 1% in its category
- Agent readiness
- 30 / 100
- AI adoption
- 0 / 100
Named in MoonLake Immunotherapeutics’s annual report 4
“...Sonelokimab ( " SLK ") , a novel tri-specific IL-17A and IL-17F inhibiting Nanobody, that we exclusively licensed from Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany ("MHKDG") and that has the potential, based on response levels seen in clinical trials, to...” SEC filing
“• we are substantially dependent on the success of our novel tri-specific Nanobody®, Sonelokimab ("SLK", also known as M1095/ALX 0761), which we license from Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany ("MHKDG");” SEC filing
“SLK is a proprietary Nanobody that was discovered by Ablynx N.V., Belgium, a Sanofi company ("Ablynx"), and previously studied by MHKDG and Avillion LLP ("Avillion") under a 2017 co-development agreement.” SEC filing
“Novation, Amended and Restatement of License Agreement, dated June 1, 2023, between MoonLake Immunotherapeutics AG, Research Corporation Technologies, Inc. and Merck KGaA (incorporated by reference to Exhibit 10.2 to the Company's Quarterly Report on Form 10-Q filed with the SEC on August 10, 2023).” SEC filing
Links are read automatically from SEC annual reports (10-K, 20-F, 40-F). In a hand check of random links, about 8 in 10 were real business relationships, so every link carries its source sentence.